[Scientific Power] Let Chinese people use original innovative medicines, he contributes

"Really let Chinese people develop new medicines and good medicines developed by Chinese scientists" -This is the goal of Chen Kai's first life.

In recent years, the reform of the drug review and approval system of my country has launched the review and approval system of the drug review. The Chinese pharmaceutical regulatory department has joined ICH. The pharmaceutical registration management system has accelerated to integrate with international standards to accelerate the listing of innovative drugs. Domestic pharmaceutical companies are going overseas. At the same time, more foreign new drugs enter the Chinese market. The flow "is accelerating, and competition is no longer limited to the domestic market.

In 2006, the state formulated a medium and long -term scientific and technological development plan, and then launched a number of major scientific and technological projects in 2008. "Major New Medicine Creation" was included in it. Academician Chen Kaixian, as the deputy chief of the technical deputy chief of the major project of "major new drug creation" technology, talked about this special introduction. The focus of the initial layout of the special implementation is to place it on the construction of the drug innovation technology platform system. In terms of R & D and key technologies, it also gives more tilt and support to corporate innovation research and development.

Picture source: official website of Shanghai University of Traditional Chinese Medicine

Chen Kaixian was born in Chongqing University Hospital on August 28, 1945. 17 years later, he was accepted by Fudan University with excellent results and entered the field of chemistry. In 1978, Chen Kai was admitted to the Shanghai Pharmaceutical Institute and became a graduate student of the famous pharmacist Ji Run. At that time, Ru Run keenly noticed that the transition from random screening to rational design was a new trend in the development of international pharmacy. Therefore, Chen Kai, a race, went to Jilin University first to open the road of studying under Tang Aoqing at Tang Aoqing, the founder of the quantum chemical chemistry.

In 1988, Chen Kai had just received a doctorate degree and was selected to go to the French Institute of Biophysics and Chemistry. During the French period, with a solid professional foundation and excellent research results, he won the Nephon Schuron Award issued by the institute, which was the first time that the award was awarded to Chinese scholars.

Academician Chen Kai, as his name: "Kai" for science and "first" for innovation. As an academician of the Chinese Academy of Sciences, he co -branded 100 academicians to make suggestions from the country have effectively promoted the vigorous development of the national pharmaceutical industry in recent years; during his time as chairman of the Shanghai Science and Technology Association, he promoted the innovation exploration of the construction of the Shanghai Science and Technology Center. During the Director of the Chinese Academy of Sciences Shanghai Drugs, the comrades of the entire Institute strived to become the leader and pioneer of the new drug research.

For a long time, the research and development of new drugs has been lacking in in -depth theoretical guidance, relying on random and blind experimental screening. This method has low efficiency, high cost, and high risk, which has become a bottleneck of new drug research.

"Previously, we were looking for possibilities by chance. In human history, important drugs were found through some chances, such as penicillin. But the efficiency of luck was too low. Sometimes it took huge manpower and material resources to screen and screen it. Thousands of compounds have nothing to find, so we must explore the new path of rational drug design. "Chen Kai said first.

In the 1960s and 1970s, the forefront of the emerging field of rational drug design came into being and developed rapidly; the study of the relationship between the drug structure also increased from the previous qualitative speculation to the quantitative calculation level.

Chen Kai first explained that the interaction of molecules and molecules can be studied by theoretical calculation methods, and can be simulated through computer simulation, and then "virtual screening" designed and high -throughput of drugs for a molecular target. Drug research is a long innovation chain. Starting from the early research and development, the mechanism of drug action, drug targets, opened a new research direction, and then carried out the design and screening of new drugs around this direction. Long.

He said that there should be good division of labor and cooperation in this innovative chain. Return to one or twenty years ago, at that time, our new drug research and development capabilities were weak, and enterprises basically did not have innovative capabilities and conditions. Limited new drug creation basically came from universities and research institutions. Even universities and research institutions are not strong, and there is a large gap with abroad.

After years of hard work, this situation has changed a lot. Nowadays, enterprises have gradually become the innovative subject of new drug research and development. In recent years, most of the new drugs that have been approved by my country each year have come from enterprises. At the same time, enterprises have gradually become the main body of innovation investment. Some head enterprises have invested more and more funds each year, up to billions of investment, and are constantly narrowing and foreign gaps. We see that the subject of innovation is changing, so the construction and layout of the innovation system should also be changed.

At present, the new drugs we develop and develop have new chemical structures and autonomous intellectual property rights. Compared with similar medicines abroad, the effects of similar medicines are generally comparable, and they are even better. of. It is usually a new mechanism and new target of a drug function abroad. We follow up again, establish a screening model for screening and structure optimization, carry out subsequent clinical pre -clinical and clinical research, and develop it into a new drug.

Now, our new drug research and development level has been improved to a new height. It is time to develop our new drugs to develop upstream and develop to original.Better, the discovery of new targets and new strategies.Therefore, universities and research institutions should pay more attention to the upstream, to the beginning of innovation, and bear more basic research and pioneering research, and new drug research will be carried out by enterprises and bear clinical clinicalPrevious research and clinical research, such a pattern is a more reasonable and higher -level cooperation, and it will also be a major trend.In

Author: Liu Jianhua

Edit: Zhao Dina

Review: Gong Zimo

- END -